#### Table e-2. Treatment-emergent adverse events (TEAEs) after the first dose in patients with ≥2 cardiovascular risk factors

|  |  |  |  |
| --- | --- | --- | --- |
| **Safety population, n (%)** | **Lasmiditan 200 mg(n=248)** | **Lasmiditan 100 mg(n=254)** | **Placebo(n=257)** |
| At least one TEAE | 102 (41.1) | 85 (33.5) | 40 (15.6) |
| **TEAEs with incidence ≥2% in any lasmiditan group and greater than placebo** |
| Dizziness | 30 (12.1) | 24 (9.4) | 7 (2.7) |
| Paresthesia | 24 (9.7) | 11 (4.3) | 6 (2.3) |
| Somnolence | 15 (6.0) | 11 (4.3) | 6 (2.3) |
| Nausea | 10 (4.0) | 9 (3.5) | 6 (2.3) |
| Fatigue | 9 (3.6) | 9 (3.5) | 1 (0.4) |
| Lethargy | 5 (2.0) | 4 (1.6) | 1 (0.4) |
| Hypoesthesia | 5 (2.0) | 1 (0.4) | 0 (0.0) |
| **Incidence of cardiovascular TEAEs** |
| Palpitations | 1 (0.4) | 1 (0.4) | 0 (0.0) |
| Tachycardia | 0 (0.0) | 1 (0.4) | 0 (0.0) |
| Left ventricular hypertrophy | 0 (0.0) | 0 (0.0) | 1 (0.4) |

TEAE=treatment-emergent adverse event (an event that started or worsened after the first dose of study medication [i.e., it did not present with the migraine] and occurred within 48 hours of dosing).